Calls for papers
-
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial… Read more . . .
-
According to Blue Lake Biotechnology, the FDA has agreed to lift a partial clinical hold on a Phase 1/2a clinical trial of BLB201 intranasal RSV vaccine in children aged 8 months to 59 months with… Read more . . .
-
Nasus Pharma announced that it has initiated a Phase 2 study of the company’s NS002 epinephrine nasal powder, which the company is developing for the treatment of anaphylaxis. The open-label PK trial is expected to… Read more . . .
-
According to ReCode Therapeutics, the FDA has cleared the 3rd part of an ongoing Phase 2 trial of nebulized RCT2100 CFTR mRNA therapy in cystic fibrosis patients, and enrollment has opened at US sites. The new… Read more . . .
-
Scottish device developer 1nhaler has announced the closing of a £1.5 million funding led by Archangels, with proceeds intended for continued development the company’s disposable single-use dry powder inhaler. The company says that funds will… Read more . . .
-
Nebulizer maker Aerogen and inhaled interferon developer Synairgen have entered a strategic partnership for development of a custom device for delivery of Synairgen’s SNG001 inhaled interferon-beta, the companies have announced, noting that the new agreement… Read more . . .
-
According to Glenmark Pharmaceuticals, China’s National Medical Products Administration (NMPA) has approved Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of allergic rhinitis. Grand Pharmaceuticals, which acquired the Chinese rights to Ryaltris… Read more . . .
-
MannKind Corporation announced that it has discontinued the Phase 3 ICoN-1 study of MNKD-101 nebulized clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease “due to futility” after analysis of data from the… Read more . . .
-
Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this… Read more . . .
-
Nasal vaccine developer CastleVax has announced the initiation of a Phase 2 study comparing its CVAX-01 intranasal COVID-19 vaccine to an mRNA-based injectable COVID-19 vaccine. The 6-month study is expected to enroll 200 previously-vaccinated adults… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland